

### Quality control and batch release aspects of Advanced Therapy Medicinal Products

Julie Veran, Michael Morrison, Florence Sabatier, Léa Chey, Fatou Mbodj, Éloïse Gennet, Véronique Andrieu, Aurélie Mahalatchimy

### ▶ To cite this version:

Julie Veran, Michael Morrison, Florence Sabatier, Léa Chey, Fatou Mbodj, et al.. Quality control and batch release aspects of Advanced Therapy Medicinal Products. Annual Conference of the European Association of Health Law (8th EAHL-Conference), Apr 2022, Ghent, Belgium. halshs-03780272

### HAL Id: halshs-03780272 https://shs.hal.science/halshs-03780272

Submitted on 19 Sep 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.























# QUALITY CONTROL AND BATCH RELEASE ASPECTS OF ADVANCED THERAPY MEDICINAL PRODUCTS

Julie VERAN<sup>1</sup>, Michael MORRISON<sup>2</sup>, Florence SABATIER<sup>3</sup>, Lea CHEY <sup>4</sup>, Fatou MBODJ <sup>4</sup>, Eloïse GENNET<sup>5</sup>, Véronique ANDRIEU<sup>6</sup>, Aurélie MAHALATCHIMY<sup>7</sup>

<sup>1</sup> Responsible of Cell therapy/Advanced Therapy Medicinal Products' production at Marseille Public Hospital (AP-HM), Biotherapies Clinical Investigation Center, France; <sup>2</sup> Senior Research Fellow in Social Sciences, Centre for Health Law and Emerging Technologies (HeLEX), University of Oxford, United Kingdom; <sup>3</sup> Professor of Hematology and Biotherapy, Pharmaceutical Sciences Faculty, C2VN INSERM INRAe 1263 AIX Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell the cell the cell the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille University, Director of the cell therapy research centre at Marseille Univer France; <sup>5</sup> Post-doctoral Researcher in Law, Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix- Marseille University, Pau & Pays de l'Adour University, Aix-en-Provence, France; <sup>6</sup> Senior lecturer in Industrial Pharmacy and Pharmaceutical Regulation, Faculty of Pharmacy, Aix-Marseille University, Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; 7 Permanent Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; 7 Permanent Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; 7 Permanent Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; 7 Permanent Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; 8 Permanent Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research Unit Microbes Evolution Phylogeny Aix-Marseille University, IRD, France; 9 Permanent Research University, IRD, France; 9 Permanent R Aix Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France.

Acknowledgements: This work has been supported by ANR-funded I-BioLex project (ANR-20-CE26-0007-01, coord. A. Mahalatchimy). M. Morrison is funded by the Leverhulme Trust through grant no RPG-2017-330.

### INTRODUCTION

Background: Biological medicinal products are products with an active substance produced or extracted from a biological source. Advanced Therapy Medicinal Products (ATMPs) are medicinal products based on genes, cells or bioengineered tissues that have been regulated in the European Union from 2007. Dedicated Good Manufacturing Practice (GMP) guidelines have been established from the European Commission in order to guarantee their quality, efficacy and safety from the development to the marketing authorisation. Consequently, GMP guidelines covering manufacture of biological active substances and medicinal products for human use including biological active substances (hereafter "biologicals") have been revised in June 2018 to prevent overlapping scope. The manufacturing of biologicals and ATMPs has to comply with guidelines that are established by the European Commission.

Research question: We hypothesized that due to biological nature of ATMPs, similarities in part of these guidelines related to quality control and batch release aspects could be evidenced in the texts. This analysis will help to understand why two different texts have been elaborated by analyzing whether they are actually based on specific considerations in terms of quality control and batch release arising from the nature of the products and the processes differences between ATMPs and other biological medicinal products.

Methods: We conducted a comparative analysis of the two following regulatory texts: Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products (focuses on from chap. 10 QUALIFICATION to the end) and Manufacture of Biological active substances and Medicinal Products for Human Use. In a first systematic approach, we identified the similarities and the specificities of texts outline (paragraph and section titles). Then, we analysed contents based on chosen relevant key words that may be diversely used in two texts (control, quality control, quality risk management, analytical technics/methods, testing etc) in order to highlight similarities and specificities in all aspects related to quality control and batch release.

### **RESULTS**

### SIMILAR REQUIREMENTS

### **Starting and raw materials**

- Compliance with legislations on quality, safety and traceability of human tissues/cells, blood/blood components, and genetically modified cells, (donation, procurement and testing)
- Appropriate level of control and requirements
- Possibility to process starting materials before the results of their testing, but release of finished product conditioned by satisfactory results

### Seed lot and cell bank system

- To prevent drift of properties during handling and storage:
- Appropriate specifications (number of generations,...)
- Risk of adventitious agents and cross contamination

### **Retained samples for QC retesting**

- "Look-back procedure" attesting for the continued suitability of the biological active
- substance. • Re-testing of retained samples from previous collections  $\rightarrow$  "last negative donation"

### In-process control

- **Ensures quality consistency**
- Happens at appropriate stages of productions.
  - Considerations for microbiological risk Level of bioburden or need to be sterile defined in MA and CTA for substances and materials at various stages Sterilization process allowing to preserve the activity of materials and excipients Aseptic process and strategies minimizing the risk of contaminants introduction (quality of starting materials, adapted environmental monitoring, use of closed

system, cleaning, use of antimicrobials or

antibiotics without interference

### **Premises and equipment for** quality control

- Apart from production. • Prevention of mix-ups and crosscontamination during testing.
- Storage space ( samples and records

### **Batch certification, release** Initial and final certification

- based on: • Environmental & analytical testing
- Defined specifications (market authorization, clinical trial authorization)
- By qualified person Management of "out of specifications"

- instructions, records/reports.
- origin, distribution chain, methods and

# controls.

( 30 years).

### • Specifications,

Documentation

**Primary** 

products'

and prevent

Compatibility of

temperatures

labels with ultra-low

spillage.

storage

- On the source,
- Traceability records

### Hazard identification/quality risk Quality risk management and risk-based approach to minimise variability of

biological processes and materials and to reduce/control contaminations. Subjects are animals, biological agents, premises, equipment and control operations

# Legend

Existing or combined sections of each text



### Disseminated requirements within each text

### containment • Safe & respect Validation of analytical methods

- characteristics. Suitability for the intended purpose Maintaining quality
  - Sterility Safety attributes
  - Critical quality attributes
  - Release criteria
  - Stability testing

### **SPECIFICITIES**

**On-going stability** 

program

> For finished products

➤ After the marketing

authorisation

the shelf-life

> Stability of

with shorter shelf-life

specifications during

### **Guidelines on Good Manufacturing Practice specific** to Advanced Therapy Medicinal Products (2017)

### Additional in vitro assays « potency testing (or proliferation assays ...)

- > After batch release as supporting data for process validation » Cell stocks
- Obtained from a limited number of passages, > Do not cover the entire life cycle of the product > Control and release conditions in accordance
- with principles of cell banks

### Novel aspects justified by specific challenges of cell-based therapy

- Complexity of products & processes + limited batch series + variability of the starting materials (especially in autologous setting) 
  Flexibility and "Risk-based" approach" for appropriate measures of quality control
- At the authorized and investigational stages, from the raw material to the final production

### **Guidelines on the Manufacturing of Biological active substances** and Medicinal Products for Human Use (2018)

Quality of starting materials or non human origin **Animal sources** 

> 2 types of sources:

- Live groups (monkeys, horses, sheeps, goats, hamsters, cattle...)
- Animal materials derived postmortem
- ➤ To comply with TSE regulations: suitability of sources/donors, traceability identification system to to control all hazards
- Strictly controlled selection of donor animals.
- Healthy
- Specific pathogen free (SPF) Raised in SPF conditions
- Bred in captivity specifically designed for the purpose of the research

Quality controls and certification aspects: measures emphasizing procurement and

quality of starting materials of animal origin, mitigation of a higher risk of low

purity and microbiological contamination, and of greater variability of biological

analytical techniques -> "risk quality management principles" for appropriate

measures of quality control

donors) to the active substance

• Focus on the process, from raw material (principally extracted from animals or

### **Controls & Testing using** animals

- > Animals used in quality
  - control assays • Generic assays, e.g.,
  - pyrogenicity,
  - Specific potency assays

# DISCUSSION/CONCLUSION

### Similar spirit of the two texts

- Based on the crucial role of manufacturing and control processes in determining the quality of such types of medicinal products
- To ensure measures related to the biological origin and the related inherent variability of such medicinal products are adopted regarding the requested standards of quality, a major determinant of safety and efficacy for the patients
- → Large set of similarities in their content on quality control and batch release, based on their common biological nature and related risks in terms of quality of starting human and raw materials, traceability, sustainability of quality, compatibility of containments, importance of process controls, strategy for initial and final certification and batch release.

### **Explicit Rationale for differences in the two texts**

- Substantial specificities due to specific risks, as presented in the scopes and general principles of the texts
- Very detailed text of 90 pages for ATMPs dated of 22/11/2017, and briefer text of 25 pages for biologicals dated of 26/06/2018 that has been revised in order to take into account the new guidelines on ATMPs.
- → Exclusive Guidelines: it is explicitly stated that the text on biologicals does not apply to ATMPs which are covered by specific guidelines.

### Questioning the relevance of having two distinct and exclusive texts

- As ATMPs are a specific category of biologicals, the levels of similarities and differences regarding quality control and batch release are variable, e.g., The "risk-based approach" for ATMPs seems matched to the "risk quality management principles" for biologicals, but the former is more prospective with the idea to anticipate and control current poorly known risks.
- Some specific requirements solely expressed in the ATMPs guidelines may be relevant to other biologicals, e.g., the validation of biological methods used for quality control and testing.
- Some specific requirements solely expressed in the text on Biologicals may be relevant to ATMPs: Because ATMPs could also in the future be designed based on xenogeneic cells and are prone to necessitate the use of raw materials of animal origin (such as cell culture or extraction reagents etc..), it can be anticipated that details of recommendations on animal sources warrant further considerations in ATMP guidelines as it is currently for biologicals.
- The rationale for some style/form differences is unclear: The vocabulary used in the two texts is very different while they have been adopted with a 7 months interval only, and it often refers to the same ideas.

The two texts are presented as exclusive, but they share common aspects.

They share common aspects related to the biological nature of the product. They could benefit from being formulated in a more similar manner to facilitate full understanding and implementation by stakeholders, especially manufacturers.

# EIGHTH EUROPEAN CONFERENCE ON HEALTH LAW

### REFERENCES - European Commission, Good Manufacturing Practice specific to Advanced Therapy Medicina

Products, 22 May 2018. - European Commission, Manufacture of Biological active substances and Medicinal Products

for Human Use, 26 June 2018. - Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on

setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, OJ L 102, 7.4.2004, p. 48-58 (and following complementary Directives).

- Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC, OJ L 33, 8.2.2003, p. 30–40.

- Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms (Recast) (Text with EEA relevance), OJ L 125, 21.5.2009, p. 75–97.

- Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC - Commission Declaration, OJ L 106, 17.4.2001, p. 1–39.